Synapse - Works

Results (13087)

PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin

Meeting Abstract

Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
Haematologica (2016)

Fulltext@MSK | Save

Results of US Intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (CALGB/Alliance 50604)

Meeting Abstract

Straus, D.; Pitcher, B.; Kostakoglu, L.; Grecula, J. C.; Hsi, E. D.; Schöder, H.; Jung, S. H.; Popplewell, L.; Chang, J. E.; Moskowitz, C.; more...
Haematologica (2016)

Fulltext@MSK | Save

Sequential brentuximab vedotin and adriamycin, vinblastine, and dacarbazine for older patients with untreated Hodgkin lymphoma: Findings from a phase II Window study

Meeting Abstract

Evens, A. M.; Hamlin, P. A.; Nabhan, C.; Advani, R.; Fanale, M.; Petrich, A.; Smith, S.; Bociek, G.; Winter, J.; Gordon, L. I.
Haematologica (2016)

Fulltext@MSK | Save

Evaluation of serum TARC levels in patients at risk of progression following autologous stem cell transplant for Hodgkin lymphoma: Results from the AETHERA trial

Meeting Abstract

Bachanova, V.; Carella, A.; Masszi, T.; Holowiecki, J.; Viviani, S.; Huebner, D.; Hunder, N.; Larsen, E.; Odegard, J.; Onsum, M.; more...
Haematologica (2016)

Fulltext@MSK | Save

Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma: Multicohort, phase 2 KEYNOTE-087 study

Meeting Abstract

Moskowitz, C.; Zinzani, P. L.; Fanale, M. A.; Armand, P.; Johnson, N.; Ribrag, V.; Radford, J.; von Tresckow, B.; Tomita, A.; Shipp, M.; more...
Haematologica (2016)

Fulltext@MSK | Save

An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials

Journal Article

Kumar, H.; Fojo, T.; Mailankody, S.
JAMA Oncology (2016)

Fulltext@MSK | Save

Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 clinical trial

Journal Article

Dickson, M. A.; Schwartz, G. K.; Louise Keohan, M.; D'Angelo, S. P.; Gounder, M. M.; Chi, P.; Antonescu, C. R.; Landa, J.; Qin, L. X.; Crago, A. M.; more...
JAMA Oncology (2016)

Fulltext@MSK | Save

Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient

Journal Article

Landgren, O.; Owen, R. G.
Cytometry Part B—Clinical Cytometry (2016)

Fulltext@MSK | Save

NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: Results from the expansion phase of a phase 1/2 study

Meeting Abstract

Liedtke, M.; Comenzo, R. L.; Landau, H.; Sanchorawala, V.; Weiss, B. M.; Zonder, J. A.; Walling, J.; Kinney, G. G.; Koller, M.; Gertz, M. A.
European Heart Journal (2016)

Fulltext@MSK | Save

Banked EBV-specific T-cells for treatment of rituximab refractory EBV plus B-cell lymphoma in solid organ transplantation recipients

Meeting Abstract

Prockop, S.; Doubrovina, E.; Sauter, C.; Suser, S.; O'Reilly, R.
American Journal of Transplantation (2016)

Fulltext@MSK | Save